Valuation: Atossa Therapeutics, Inc.

Market Cap 25.95M 23.16M 21.38M 19.4M 36.33M 2.46B 36.89M 257M 102M 1.29B 97.35M 95.29M 4.07B P/E 2026 *
-0.69x
P/E 2027 * -0.93x
Enterprise Value 25.95M 23.16M 21.38M 19.4M 36.33M 2.46B 36.89M 257M 102M 1.29B 97.35M 95.29M 4.07B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-4.41%
1 week-1.89%
Current month+33.33%
1 month+15.04%
3 months+7.00%
6 months-56.30%
Current year-70.62%
1 week 2.38
Extreme 2.38
2.85
1 month 1.82
Extreme 1.82
3.12
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
14.85
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
43.62
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 31/03/2009
Director of Finance/CFO 50 13/10/2025
Chief Tech/Sci/R&D Officer - 30/09/2025
Director TitleAgeSince
Chairman 75 31/03/2009
Director/Board Member 64 31/03/2009
Director/Board Member 79 30/06/2011
Date Insider Type Main position Quantity % Market Cap. Importance
12/05/26
Ensisheim Partners LLC
OtherCompany 0 0% -
12/05/26 Free

Director

10,000 0.1161%
12/05/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
-4.41%-1.89%-81.16%-73.74% 27.14M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+3.11%+10.29%+72.56% 54.89B
+0.57%+4.64%+12.82%+89.79% 53.28B
+0.37%+3.07%+28.23%+51.53% 45.81B
-1.21%+0.95%+20.44%+128.58% 43.46B
-0.37%-1.20%+252.94%+568.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average -0.19%+0.56%+36.70%+99.25% 38.19B
Weighted average by Cap. +0.38%+0.55%+48.16%+122.10%

Financials

2026 *2027 *
Net sales - -
Net income -35.3M -31.51M -29.09M -26.39M -49.42M -3.35B -50.19M -350M -139M -1.75B -132M -130M -5.53B -38.03M -33.95M -31.34M -28.44M -53.24M -3.61B -54.07M -377M -149M -1.89B -143M -140M -5.96B
Net Debt - -
Projected Income Statement - Annual - Atossa Therapeutics, Inc.
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
23/10/26 US$2.600 -4.41% 76,910
22/10/26 US$2.720 +7.51% 90,656
21/10/26 US$2.530 -0.39% 189,632
20/10/26 US$2.540 -0.78% 36,755
19/10/26 US$2.560 -12.03% 80,522
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Atossa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.600USD
Average target price
19.00USD
Spread / Average Target
+630.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atossa Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATOS Stock